A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The purpose of this study is to evaluate how well JNJ-101556143 plus Best Supportive Care (BSC) improves overall survival (the length of time a participant remains alive) compared with placebo plus BSC in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). mAPMR is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone treatments designed to block male hormones (androgens).
Epistemonikos ID: d15497bf9f724dd3fa67fa84171c5623e6ae199c
First added on: Oct 31, 2026